—
PHILADELPHIA and LONDON, October 15PHILADELPHIA and LONDON, October 15 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, announced today the launch of Thomson Pharma KOLexperts, a new solution designed to help pharmaceutical organizations identify, verify, and develop productive relationships with key opinion leaders (KOLs) and scientific experts. It is the first solution available to the industry that allows users to rank life sciences KOLs with a range of objective metrics. Designed for scientific expertise identification, Thomson Pharma KOLexperts offers a variety of tools to find experts with specific scientific competencies.
"Leveraging external experts is crucial to the success of drug development today. Our customers increasingly want to build their research, clinical and marketing teams based on objective criteria such as scientific credibility, but lack the information and analysis to do so. We have harnessed Thomson Reuter's long legacy in information aggregation, citation analysis, and scientific expertise to deliver a first-in-class solution to our customers," said Wendy Hamilton, vice president, product strategy, Pharmaceutical and Chemicals Markets, Thomson Reuters. "When designing Thomson Pharma KOLexperts, our objective was to create a life sciences 'Who's Who' of experts that can be leveraged at any point from discovery to market. We utilize trusted data that is skillfully indexed, carefully researched, and always up to date."
Users of Thomson Pharma KOLexperts can search for and view experts in a therapy area of interest, and determine a scientist's ranking at a glance as extrapolated from cited work, research activity, speaking engagements and other promotional or educational efforts. As there is no one ranking system that addresses all priorities and considerations, the customer can adjust the ranking approach directly within the product using simple point and click. The solution brings together the core databases of Thomson Reuters with key external data sources to offer an up-to-the-minute snapshot of an expert's status. It also allows users to identify the scientists recognized as leaders in their therapeutic areas and highlight new and emerging stars.
"In the face of an emerging regulatory environment that demands greater transparency into KOL selection and fair remuneration, objectively identifying KOLs based on scientific merit paves the way for success throughout the drug development and marketing process. Thomson Pharma KOLexperts is the first product to enable the optimal alignment of KOLs with the business strategies of individual life sciences organizations based on science, not subjectivity," added Hamilton.
Thomson Pharma KOLexperts can be adapted to the unique needs of each subscribing company. In addition to the standard product, new types of expert profiles can be created upon demand based on customer request.
For more information, visit: http://www.thomsonreuters.com/products_services/scientific/kolexperts
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to www.thomsonreuters.com
Web site: http://www.thomsonreuters.com http://www.thomsonreuters.com/products_services/scientific/kolexperts
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
